

INTERNATIONAL BIOTECHNOLOGY TRUST PLC ("IBT")

Latest Factsheet and Blog

IBT's factsheet for the month ended 31 October 2024 is now available directly via its web page. Please click [here](#), then 'latest factsheet'.

Obesity has long been a significant global health challenge, particularly in the western world, due to the implications it can have for associated conditions such as heart disease, diabetes and certain cancers. Until recently, treatments focused on lifestyle changes and pharmacological interventions like appetite suppressants and fat absorption inhibitors. However, these early drugs often had limited efficacy and significant side effects, leading to a persistent demand for more effective solutions. Here, we explore the continued innovation taking place in the obesity medication space.

The blog can be read here:

<https://www.schroders.com/en-gb/uk/individual/content/the-future-of-obesity/>

To sign up for IBT updates by email, please click [here](#).

ENDS

Enquiries:

Schroder Investment Management Limited

Kirsty Preston (PR) 020 7658 6000

Kerry Higgins (Company Secretary) 020 7658 6000

Kaso Legg Communications (Financial PR)

Charles Gorman
Henry Taylor
Effie Aye Maung Hider

IBT@kl-communications.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAFXLFBZLLFFBQ